Xenon Pharmaceuticals Inc (XENE)

$64.00 +1.74 (2.79%)
Market Cap 6.06B
Revenue (ttm) 7.50M
Net Income (ttm) -345.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,612.13%
Debt to Equity Ratio 0.00
Volume 381,563
Avg Vol 1,492,664
Day's Range N/A - N/A
Shares Out 96.67M
Stochastic %K 19%
Beta 0.61
Analysts Strong Sell
Price Target $80.31

Company Profile

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as majo...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 484 3300
Address:
200-3650 Gilmore Way, Burnaby, Canada
Quantumup
Quantumup Aug. 3 at 8:22 PM
William Blair also said in its 7/28, $RAPP 🏁it ests lead asset, RAP-219, could reach $2.2B US peak sales in focal onset seizure (FOS)—w/ possibilities to expand its mkt oppy into the PGTCS population/bipolar mania. $PRAX $XENE ESAIY BHVN OVID Here's what else William blair had to say in its 7/28 initiation report: https://x.com/Quantumup1/status/2084374154929680452?s=20
0 · Reply
momo999
momo999 Aug. 3 at 3:18 PM
$XENE this stock needs some pumpers
0 · Reply
Cache_Money
Cache_Money Aug. 3 at 3:34 AM
$BHVN Did a bit more DD on this company and I don’t like that they’ve barely got enough cash to even make it to their two phase 2 trial readouts. $XENE’s Azetukalner also sets the bar pretty high for efficacy and still is pretty well-tolerated, with close to placebo rates of somnolence but some increased dizziness that Opakalim doesn’t seem to have. It doesn’t seem like Azetukalner has off-target activity at GABA as Biohaven’s leadership has implied. Rather, the differentiated safety profile seems to be more likely due to PK differences, as Azetukalner has a much longer half-life in the body and thus may achieve higher receptor saturation. This also may or may not give Azetukalner an edge on efficacy. There is also the possible explanation that the dizziness may be due to Azetukalner having some activity at Kv7.4 in the inner ear. I personally prefer the safer drug with less accumulation but the efficacy needs to be pretty much hard-matched. Very high-risk play here.
1 · Reply
Machiaveltrade
Machiaveltrade Jul. 10 at 3:11 PM
$XENE add
0 · Reply
techj2022
techj2022 Jul. 10 at 1:50 AM
$RAPP, $XENE best drugs for focal seizure imho.
1 · Reply
AXLFI_HQ
AXLFI_HQ Jul. 10 at 12:56 AM
The most recent Dark Pools signal on $XENE triggered on 2026-07-09. The expected return for the selected horizon is +14.58% with a historical profit probability of +60.71%. Learn more: https://axlfi.com/factor-analysis?symbol=XENE&factor=dark_pools&timeframe=daily
0 · Reply
kimjun36
kimjun36 Jul. 9 at 5:54 PM
$XENE
0 · Reply
forprofit12
forprofit12 Jul. 9 at 5:13 PM
$XENE doubled my position. This is a prime buyout candidate.
0 · Reply
topstockalerts
topstockalerts Jul. 9 at 1:10 AM
$XENE that was a very healthy way to absorb selling.
0 · Reply
Timefortendies77
Timefortendies77 Jul. 8 at 11:23 PM
$XENE I'm going to rip heads for whoever leaked this, haha
0 · Reply
Latest News on XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2026, 4:01 PM EDT - 3 days ago

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon to Report Q2 2026 Financial Results on August 6, 2026

Jul 30, 2026, 4:01 PM EDT - 4 days ago

Xenon to Report Q2 2026 Financial Results on August 6, 2026

Xenon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 9:55 AM EDT - 2 months ago

Xenon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan

2026-05-27T12:35:12.000Z - 2 months ago

Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan

Xenon Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:30 AM EDT - 2 months ago

Xenon Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

Xenon Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 14, 2026, 11:00 AM EDT - 2 months ago

Xenon Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan

2026-05-12T12:13:56.000Z - 3 months ago

Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan

Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo

2026-05-10T14:21:28.000Z - 3 months ago

Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo

PRAX

Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham

2026-05-08T22:33:24.000Z - 3 months ago

Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham

Xenon Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Xenon Pharmaceuticals Earnings Call Transcript: Q1 2026

Xenon Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Xenon Pharmaceuticals Earnings release: Q1 2026

Xenon Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Xenon Pharmaceuticals Quarterly report: Q1 2026

Xenon Reports Q1 2026 Financial Results and Provides Business Update

May 7, 2026, 4:01 PM EDT - 3 months ago

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

May 7, 2026, 8:44 AM EDT - 3 months ago

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Xenon to Report Q1 2026 Financial Results on May 7, 2026

Apr 30, 2026, 4:01 PM EDT - 3 months ago

Xenon to Report Q1 2026 Financial Results on May 7, 2026

Xenon Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 22, 2026, 11:30 AM EDT - 3 months ago

Xenon Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Xenon Pharmaceuticals Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

Xenon Pharmaceuticals Proxy statement: Proxy filing

Xenon Pharmaceuticals Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

Xenon Pharmaceuticals Proxy statement: Proxy filing

Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study

2026-04-20T00:46:25.000Z - 3 months ago

Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Apr 19, 2026, 6:00 PM EDT - 3 months ago

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon to Present at Upcoming Investor Conferences

Apr 15, 2026, 8:30 AM EDT - 3 months ago

Xenon to Present at Upcoming Investor Conferences

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Apr 7, 2026, 8:30 AM EDT - 4 months ago

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush

2026-03-16T12:01:08.000Z - 5 months ago

Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Mar 12, 2026, 4:01 PM EDT - 5 months ago

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

2026-03-11T10:00:16.000Z - 5 months ago

Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Mar 10, 2026, 10:39 PM EDT - 5 months ago

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush

2026-03-10T12:22:22.000Z - 5 months ago

Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush

Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim

2026-03-10T10:55:46.000Z - 5 months ago

Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim

Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo

2026-03-10T10:52:56.000Z - 5 months ago

Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo

Biohaven price target raised to $27 from $24 at Goldman Sachs

2026-03-10T10:30:50.000Z - 5 months ago

Biohaven price target raised to $27 from $24 at Goldman Sachs

BHVN

Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs

2026-03-10T10:25:34.000Z - 5 months ago

Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs

Xenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright

2026-03-10T10:16:02.000Z - 5 months ago

Xenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright

Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank

2026-03-10T08:40:35.000Z - 5 months ago

Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank

Xenon Pharmaceuticals announces $500M common shares offering

2026-03-09T20:05:45.000Z - 5 months ago

Xenon Pharmaceuticals announces $500M common shares offering

Xenon Pharmaceuticals Announces Proposed Public Offering

Mar 9, 2026, 4:01 PM EDT - 5 months ago

Xenon Pharmaceuticals Announces Proposed Public Offering

Xenon Pharmaceuticals price target raised to $100 from $65 at Jefferies

2026-03-09T20:00:12.000Z - 5 months ago

Xenon Pharmaceuticals price target raised to $100 from $65 at Jefferies

Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital

2026-03-09T19:55:26.000Z - 5 months ago

Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital

Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate

2026-03-09T17:50:26.000Z - 5 months ago

Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate

BHVN

Xenon Pharmaceuticals Transcript: Study result

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Xenon Pharmaceuticals Transcript: Study result

Xenon Pharmaceuticals Press release: Study result

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Xenon Pharmaceuticals Press release: Study result

Xenon Pharmaceuticals Slides: Study result

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Xenon Pharmaceuticals Slides: Study result

Xenon Pharma's epilepsy drug meets main goal in late-stage trial

Mar 9, 2026, 7:26 AM EDT - 5 months ago

Xenon Pharma's epilepsy drug meets main goal in late-stage trial

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

Mar 8, 2026, 2:00 PM EDT - 5 months ago

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 4:01 PM EST - 5 months ago

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

Xenon Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 4:00 PM EST - 5 months ago

Xenon Pharmaceuticals Annual report: Q4 2025

Xenon Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 4:00 PM EST - 5 months ago

Xenon Pharmaceuticals Earnings release: Q4 2025

Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study

Jan 20, 2026, 8:46 AM EST - 7 months ago

Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study

Xenon Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 7 months ago

Xenon Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Xenon Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 7 months ago

Xenon Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:30 AM EST - 7 months ago

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 7 months ago

Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

Xenon Pharmaceuticals Transcript: Status Update

Dec 10, 2025, 10:00 AM EST - 8 months ago

Xenon Pharmaceuticals Transcript: Status Update

Xenon Pharmaceuticals Slides: Status Update

Dec 10, 2025, 10:00 AM EST - 8 months ago

Xenon Pharmaceuticals Slides: Status Update

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Dec 5, 2025, 9:00 AM EST - 8 months ago

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

Dec 3, 2025, 8:30 AM EST - 8 months ago

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Nov 25, 2025, 8:30 AM EST - 9 months ago

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Xenon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:30 AM EST - 9 months ago

Xenon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Xenon Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 3:20 PM EST - 9 months ago

Xenon Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Xenon Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Xenon Pharmaceuticals Earnings Call Transcript: Q3 2025

Xenon Pharmaceuticals Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Xenon Pharmaceuticals Quarterly report: Q3 2025

Xenon Pharmaceuticals Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Xenon Pharmaceuticals Earnings release: Q3 2025

Xenon Reports Third Quarter 2025 Financial Results & Business Update

Nov 3, 2025, 4:01 PM EST - 9 months ago

Xenon Reports Third Quarter 2025 Financial Results & Business Update

Xenon to Report Q3 2025 Financial Results on November 3, 2025

Oct 27, 2025, 8:30 AM EDT - 10 months ago

Xenon to Report Q3 2025 Financial Results on November 3, 2025

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

Oct 16, 2025, 8:30 AM EDT - 10 months ago

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

Xenon Pharmaceuticals Transcript: Study Update

Oct 6, 2025, 11:30 AM EDT - 10 months ago

Xenon Pharmaceuticals Transcript: Study Update

Xenon Pharmaceuticals Slides: Study Update

Oct 6, 2025, 11:30 AM EDT - 10 months ago

Xenon Pharmaceuticals Slides: Study Update

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

Sep 25, 2025, 4:01 PM EDT - 11 months ago

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

Xenon Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Xenon Pharmaceuticals Earnings Call Transcript: Q2 2025

Xenon Pharmaceuticals Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Xenon Pharmaceuticals Quarterly report: Q2 2025

Xenon Pharmaceuticals Earnings release: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Xenon Pharmaceuticals Earnings release: Q2 2025

Xenon Reports Second Quarter 2025 Financial Results & Business Update

Aug 11, 2025, 4:01 PM EDT - 1 year ago

Xenon Reports Second Quarter 2025 Financial Results & Business Update

Xenon Pharmaceuticals Slides: Corporate Presentation

Aug 10, 2025, 6:00 PM EDT - 1 year ago

Xenon Pharmaceuticals Slides: Corporate Presentation

Xenon to Report Q2 2025 Financial Results on August 11, 2025

Aug 4, 2025, 8:01 AM EDT - 1 year ago

Xenon to Report Q2 2025 Financial Results on August 11, 2025

Xenon Joins the Russell 3000® and Russell 2000® Indexes

Jun 27, 2025, 4:01 PM EDT - 1 year ago

Xenon Joins the Russell 3000® and Russell 2000® Indexes

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

Xenon Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 3:20 PM EDT - 1 year ago

Xenon Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 4:01 PM EDT - 1 year ago

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Xenon Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 10:30 AM EDT - 1 year ago

Xenon Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum

May 15, 2025, 8:49 AM EDT - 1 year ago

Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum

Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 4:01 PM EDT - 1 year ago

Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Xenon Pharmaceuticals Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Xenon Pharmaceuticals Earnings Call Transcript: Q1 2025

Xenon Pharmaceuticals Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Xenon Pharmaceuticals Quarterly report: Q1 2025

Xenon Pharmaceuticals Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Xenon Pharmaceuticals Earnings release: Q1 2025

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:01 PM EDT - 1 year ago

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update

Xenon to Report Q1 2025 Financial Results on May 12, 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Xenon to Report Q1 2025 Financial Results on May 12, 2025

Xenon Pharmaceuticals Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Xenon Pharmaceuticals Proxy statement: Proxy Filing

Xenon Pharmaceuticals Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Xenon Pharmaceuticals Proxy statement: Proxy Filing

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Apr 4, 2025, 8:30 AM EDT - 1 year ago

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

Mar 31, 2025, 2:05 PM EDT - 1 year ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI ALNY RYTM VRTX

Xenon Pharmaceuticals Transcript: Stifel 2025 Virtual CNS Forum

Mar 19, 2025, 12:00 PM EDT - 1 year ago

Xenon Pharmaceuticals Transcript: Stifel 2025 Virtual CNS Forum

Xenon to Present at Stifel 2025 Virtual CNS Forum

Mar 12, 2025, 4:01 PM EDT - 1 year ago

Xenon to Present at Stifel 2025 Virtual CNS Forum

Xenon Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 10:30 AM EST - 1 year ago

Xenon Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Xenon Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Xenon Pharmaceuticals Earnings Call Transcript: Q4 2024

Xenon Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Xenon Pharmaceuticals Annual report: Q4 2024

Xenon Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Xenon Pharmaceuticals Earnings release: Q4 2024

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

Feb 27, 2025, 4:01 PM EST - 1 year ago

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

Feb 25, 2025, 4:01 PM EST - 1 year ago

Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

Feb 20, 2025, 4:01 PM EST - 1 year ago

Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

XENON Systems Partners with Netris to Deliver Multi-tenant GPU Cloud Networking Solutions for AI/ML Cloud Providers in the Region

Feb 12, 2025, 12:00 PM EST - 1 year ago

XENON Systems Partners with Netris to Deliver Multi-tenant GPU Cloud Networking Solutions for AI/ML Cloud Providers in the Region

Xenon Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 12:45 PM EST - 1 year ago

Xenon Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Xenon Pharmaceuticals Slides: FY 2025

Jan 13, 2025, 12:45 PM EST - 1 year ago

Xenon Pharmaceuticals Slides: FY 2025

Xenon Outlines Key Corporate Milestone Opportunities for 2025

Jan 13, 2025, 8:30 AM EST - 1 year ago

Xenon Outlines Key Corporate Milestone Opportunities for 2025

Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:30 AM EST - 1 year ago

Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

Dec 6, 2024, 4:01 PM EST - 1 year ago

Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

Nov 25, 2024, 8:30 AM EST - 1 year ago

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

Xenon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 8:30 AM EST - 1 year ago

Xenon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Xenon Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 9:10 AM EST - 1 year ago

Xenon Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Xenon Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Xenon Pharmaceuticals Earnings Call Transcript: Q3 2024

Xenon Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Xenon Pharmaceuticals Quarterly report: Q3 2024

Xenon Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Xenon Pharmaceuticals Earnings release: Q3 2024

Xenon Reports Q3 2024 Financial Results and Business Update

Nov 12, 2024, 4:01 PM EST - 1 year ago

Xenon Reports Q3 2024 Financial Results and Business Update

Xenon to Report Q3 2024 Financial Results on November 12, 2024

Nov 5, 2024, 4:01 PM EST - 1 year ago

Xenon to Report Q3 2024 Financial Results on November 12, 2024

Xenon Pharmaceuticals Transcript: BofA Securities CNS Therapeutics Virtual Conference 2024

Oct 7, 2024, 11:40 AM EDT - 1 year ago

Xenon Pharmaceuticals Transcript: BofA Securities CNS Therapeutics Virtual Conference 2024

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

Oct 2, 2024, 4:28 PM EDT - 1 year ago

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

Sep 9, 2024, 8:30 AM EDT - 2 years ago

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

Xenon Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Xenon Pharmaceuticals Earnings Call Transcript: Q2 2024

Xenon Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Xenon Pharmaceuticals Quarterly report: Q2 2024

Xenon Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Xenon Pharmaceuticals Earnings release: Q2 2024

Xenon Reports Q2 2024 Financial Results and Business Update

Aug 8, 2024, 4:01 PM EDT - 2 years ago

Xenon Reports Q2 2024 Financial Results and Business Update

Quantumup
Quantumup Aug. 3 at 8:22 PM
William Blair also said in its 7/28, $RAPP 🏁it ests lead asset, RAP-219, could reach $2.2B US peak sales in focal onset seizure (FOS)—w/ possibilities to expand its mkt oppy into the PGTCS population/bipolar mania. $PRAX $XENE ESAIY BHVN OVID Here's what else William blair had to say in its 7/28 initiation report: https://x.com/Quantumup1/status/2084374154929680452?s=20
0 · Reply
momo999
momo999 Aug. 3 at 3:18 PM
$XENE this stock needs some pumpers
0 · Reply
Cache_Money
Cache_Money Aug. 3 at 3:34 AM
$BHVN Did a bit more DD on this company and I don’t like that they’ve barely got enough cash to even make it to their two phase 2 trial readouts. $XENE’s Azetukalner also sets the bar pretty high for efficacy and still is pretty well-tolerated, with close to placebo rates of somnolence but some increased dizziness that Opakalim doesn’t seem to have. It doesn’t seem like Azetukalner has off-target activity at GABA as Biohaven’s leadership has implied. Rather, the differentiated safety profile seems to be more likely due to PK differences, as Azetukalner has a much longer half-life in the body and thus may achieve higher receptor saturation. This also may or may not give Azetukalner an edge on efficacy. There is also the possible explanation that the dizziness may be due to Azetukalner having some activity at Kv7.4 in the inner ear. I personally prefer the safer drug with less accumulation but the efficacy needs to be pretty much hard-matched. Very high-risk play here.
1 · Reply
Machiaveltrade
Machiaveltrade Jul. 10 at 3:11 PM
$XENE add
0 · Reply
techj2022
techj2022 Jul. 10 at 1:50 AM
$RAPP, $XENE best drugs for focal seizure imho.
1 · Reply
AXLFI_HQ
AXLFI_HQ Jul. 10 at 12:56 AM
The most recent Dark Pools signal on $XENE triggered on 2026-07-09. The expected return for the selected horizon is +14.58% with a historical profit probability of +60.71%. Learn more: https://axlfi.com/factor-analysis?symbol=XENE&factor=dark_pools&timeframe=daily
0 · Reply
kimjun36
kimjun36 Jul. 9 at 5:54 PM
$XENE
0 · Reply
forprofit12
forprofit12 Jul. 9 at 5:13 PM
$XENE doubled my position. This is a prime buyout candidate.
0 · Reply
topstockalerts
topstockalerts Jul. 9 at 1:10 AM
$XENE that was a very healthy way to absorb selling.
0 · Reply
Timefortendies77
Timefortendies77 Jul. 8 at 11:23 PM
$XENE I'm going to rip heads for whoever leaked this, haha
0 · Reply
LUNR_SpacEx_onSteroids
LUNR_SpacEx_onSteroids Jul. 8 at 11:03 PM
$CMPS $PRAX $RAPP $XBI $XENE 🤔 WAIT JUST A SECOND HERE; 🤑 HC Wainwright SAYS CMPS Ready to SOAR TO $70. That’s MORE THAN 5X 🤑MINIMUM A TRIPLE 💰 💰💰Play
1 · Reply
Brianum2011
Brianum2011 Jul. 8 at 10:22 PM
$XENE Why going up?
1 · Reply
forprofit12
forprofit12 Jul. 8 at 9:58 PM
$XENE looks like I need to add more. Definitely something going on here
1 · Reply
JFais
JFais Jul. 8 at 8:51 PM
$XENE - is this a Centerview deal? Pattern looks familiar
0 · Reply
KenArcher
KenArcher Jul. 8 at 8:26 PM
$XENE when nothing else is working, hot money flees to bio. Oversized move. Ain’t no buyout happening here!
1 · Reply
Flyingkitty
Flyingkitty Jul. 8 at 8:20 PM
$IOVA $XENE And just like that is going to happen Iovans... I think XENE is getting bought....
0 · Reply
RunnerSignals
RunnerSignals Jul. 8 at 7:59 PM
52-week highs ​$PENG $XENE $VLO $DINO $SGHC
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Jul. 8 at 7:42 PM
$XENE printed a new 52-week high today
0 · Reply
Alpha_Ascendant
Alpha_Ascendant Jul. 7 at 2:53 PM
$SBIO $APGE $XENE $CGON has delivered 111% returns over the past year, its holdings having seen notable buyouts & clinical milestones. Its focus on strong cash positions, Phase 2/3 assets, & near-term catalysts, creates a portfolio of high-vol, high-alpha lottery tickets: https://seekingalpha.com/article/4920327-sbio-biotech-breakthrough-opportunities-screened-for-cash-burn
0 · Reply
Wischmop
Wischmop Jun. 28 at 5:19 AM
$XENE https://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-inc-nasdaqxene-receives-consensus-rating-of-buy-from-brokerages-2026-05-06/ schrieb mo
0 · Reply
ObeCalp
ObeCalp Jun. 26 at 8:02 PM
$XENE Put in my buy limit order before that end of day pop so it didn't execute... hopefully I won't have to execute myself (not literally but maybe a couple punches to my face).
0 · Reply
JFais
JFais Jun. 22 at 9:24 PM
$BHVN $XENE
0 · Reply